Tempus AI, Inc (TEM)

NASDAQ: TEM · Real-Time Price · USD
58.83
-4.11 (-6.53%)
Dec 3, 2024, 11:33 AM EST - Market open
-6.53%
Market Cap 9.26B
Revenue (ttm) 640.44M
Net Income (ttm) -800.71M
Shares Out 157.45M
EPS (ttm) -8.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 555,693
Open 62.47
Previous Close 62.94
Day's Range 58.16 - 62.47
52-Week Range 22.89 - 79.49
Beta n/a
Analysts Buy
Price Target 55.00 (-6.51%)
Earnings Date Nov 4, 2024

About TEM

Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company also offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to ph... [Read more]

Sector Healthcare
IPO Date Jun 14, 2024
Employees 1,952
Stock Exchange NASDAQ
Ticker Symbol TEM
Full Company Profile

Financial Performance

In 2023, Tempus AI's revenue was $531.82 million, an increase of 65.85% compared to the previous year's $320.67 million. Losses were -$265.96 million, -20.35% less than in 2022.

Financial numbers in USD Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for TEM stock is "Buy." The 12-month stock price forecast is $55.0, which is a decrease of -6.51% from the latest price.

Price Target
$55.0
(-6.51% downside)
Analyst Consensus: Buy
Stock Forecasts

News

Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Piper Sandler 36th Annu...

8 days ago - Business Wire

The Big 3: CRWD, CVNA, TEM

@ProsperTradingAcademy's Charles Moon is bullish on all of today's Big 3. He points to Crowdstrike's (CRWD) recovery and Carvana (CVNA) coiling to the upside as positive markers but warns of volatilit...

Other symbols: CRWDCVNA
10 days ago - Schwab Network

Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation

Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecul...

20 days ago - Seeking Alpha

Tempus Molecular Profiling Integration Now Available Through Flatiron's OncoEMR®

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the collaboration with Flatiron...

21 days ago - Business Wire

Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Acti...

22 days ago - Business Wire

Tempus AI, Inc. (TEM) Q3 2024 Earnings Call Transcript

Tempus AI, Inc. (NASDAQ:TEM) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer...

24 days ago - Seeking Alpha

Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced nine abstracts were accepted fo...

25 days ago - Business Wire

Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the clinical launch of its Immu...

25 days ago - Business Wire

Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarte...

4 weeks ago - Business Wire

Tempus to Report Third Quarter 2024 Financial Results on November 4

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday,...

4 weeks ago - Business Wire

Tempus and Northwestern Medicine Announce Collaboration to Bring Practical Application of AI to Healthcare

CHICAGO--(BUSINESS WIRE)--Tempus, a leader in artificial intelligence and precision medicine, and Northwestern Medicine, Chicago's premier integrated academic health system, today announced a collabor...

4 weeks ago - Business Wire

Tempus: Attempting To Lead The AI Revolution In Healthcare

Tempus AI, Inc, a healthcare technology company, has shown DECENT gains since its listing in June, outperforming the Nasdaq and AI-themed stock portfolios. TEM aims to leverage AI and ML and revolutio...

4 weeks ago - Seeking Alpha

Tempus to Report Third Quarter 2024 Financial Results on November 7

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursda...

5 weeks ago - Business Wire

Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announces an expansion to its collaborati...

Other symbols: TAK
2 months ago - Business Wire

Tempus Announces Four Abstracts Accepted For Presentation at the European Society for Medical Oncology Congress 2024

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced four abstracts were accepted fo...

2 months ago - Business Wire

Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the beta launch of a patient-fa...

2 months ago - Business Wire

Tempus Announces Real World Data Collaboration with BioNTech

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM, “Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a multi-year collabor...

Other symbols: BNTX
3 months ago - Business Wire

Tempus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley 22nd Ann...

3 months ago - Business Wire

Undercovered Dozen: Delcath Systems, Bavarian Nordic, Tempus AI, Journey Energy +

In this article, Seeking Alpha editors highlight 12 ideas published last week focused on stocks with less coverage on our platform. Energy ideas are prevalent in this edition with articles highlighted...

Other symbols: DCTH
3 months ago - Seeking Alpha

Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'

Tempus AI provides an end-to-end diagnostic platform connecting clinical, molecular, and image data for physicians and pharmaceutical companies. The company's key competitive advantages include broad ...

3 months ago - Seeking Alpha

Cathie Wood bets big on Tempus AI: Is it the next big thing in health-tech?

Cathie Wood, a prominent advocate for innovative technologies, is making a bold bet on artificial intelligence with her latest investment in Tempus AI Inc. (NASDAQ: TEM).  Known for her strategic focu...

3 months ago - Invezz

BerGenBio Second Quarter Results 2024: Solid clinical and financial progress

BERGEN, Norway , Aug. 21, 2024 /PRNewswire/ -- BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, ...

3 months ago - PRNewsWire

Tempus AI Soars To New Highs, Investments From Google And SoftBank Boost Bullish Sentiment

Tempus AI Inc. TEM, a cutting-edge healthcare diagnostics company, has been on a tear. The stock established a new high of $47.81 on Thursday.

3 months ago - Benzinga

Personalis and Tempus Announce Expanded Collaboration

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL) and Tempus AI, Inc. (Nasdaq: TEM) announced today that the companies have expanded their commercial relationship. The companies agreed...

Other symbols: PSNL
3 months ago - Business Wire

NPJ Precision Oncology Publishes Tempus Study on Validation of its HLA-LOH Investigational Assay

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that the validation study of it...

4 months ago - Business Wire